Pathological Safety Assessment in Preclinical Neurothrombectomy Studies

Taylor A. Spangler, Scott A Katzman

Research output: Contribution to journalArticle

Abstract

The design, production, and preclinical testing of neurothrombectomy devices is in a burgeoning phase as the demand escalates for safe and reliable treatment options following neurovascular stroke. Currently, there is a paucity of published data describing the development of iatrogenic vascular lesions occurring secondary to neurothrombectomy procedures. In an effort to test new devices, demonstrate device safety, satisfy regulatory requirements, and develop an understanding of the potential for associated vascular pathology, investigators are establishing appropriate methodology in suitable animal models. Significant challenges exist in identifying a single animal species that can be consistently utilized in all phases of device development. These aforementioned challenges are underscored by the intricacies of neurovascular pathology, thrombovascular interactions, and vascular responses to injury.

Original languageEnglish (US)
JournalToxicologic Pathology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pathology
Blood Vessels
Animals
Safety devices
Safety
Equipment and Supplies
Equipment Safety
Testing
Animal Models
Stroke
Research Personnel
Wounds and Injuries

Keywords

  • endovascular injury
  • histopathology
  • neurothrombectomy
  • porcine
  • preclinical

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Toxicology
  • Cell Biology

Cite this

Pathological Safety Assessment in Preclinical Neurothrombectomy Studies. / Spangler, Taylor A.; Katzman, Scott A.

In: Toxicologic Pathology, 01.01.2019.

Research output: Contribution to journalArticle

@article{1415ab76c1b1448497142d284dcbc867,
title = "Pathological Safety Assessment in Preclinical Neurothrombectomy Studies",
abstract = "The design, production, and preclinical testing of neurothrombectomy devices is in a burgeoning phase as the demand escalates for safe and reliable treatment options following neurovascular stroke. Currently, there is a paucity of published data describing the development of iatrogenic vascular lesions occurring secondary to neurothrombectomy procedures. In an effort to test new devices, demonstrate device safety, satisfy regulatory requirements, and develop an understanding of the potential for associated vascular pathology, investigators are establishing appropriate methodology in suitable animal models. Significant challenges exist in identifying a single animal species that can be consistently utilized in all phases of device development. These aforementioned challenges are underscored by the intricacies of neurovascular pathology, thrombovascular interactions, and vascular responses to injury.",
keywords = "endovascular injury, histopathology, neurothrombectomy, porcine, preclinical",
author = "Spangler, {Taylor A.} and Katzman, {Scott A}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/0192623319826066",
language = "English (US)",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Pathological Safety Assessment in Preclinical Neurothrombectomy Studies

AU - Spangler, Taylor A.

AU - Katzman, Scott A

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The design, production, and preclinical testing of neurothrombectomy devices is in a burgeoning phase as the demand escalates for safe and reliable treatment options following neurovascular stroke. Currently, there is a paucity of published data describing the development of iatrogenic vascular lesions occurring secondary to neurothrombectomy procedures. In an effort to test new devices, demonstrate device safety, satisfy regulatory requirements, and develop an understanding of the potential for associated vascular pathology, investigators are establishing appropriate methodology in suitable animal models. Significant challenges exist in identifying a single animal species that can be consistently utilized in all phases of device development. These aforementioned challenges are underscored by the intricacies of neurovascular pathology, thrombovascular interactions, and vascular responses to injury.

AB - The design, production, and preclinical testing of neurothrombectomy devices is in a burgeoning phase as the demand escalates for safe and reliable treatment options following neurovascular stroke. Currently, there is a paucity of published data describing the development of iatrogenic vascular lesions occurring secondary to neurothrombectomy procedures. In an effort to test new devices, demonstrate device safety, satisfy regulatory requirements, and develop an understanding of the potential for associated vascular pathology, investigators are establishing appropriate methodology in suitable animal models. Significant challenges exist in identifying a single animal species that can be consistently utilized in all phases of device development. These aforementioned challenges are underscored by the intricacies of neurovascular pathology, thrombovascular interactions, and vascular responses to injury.

KW - endovascular injury

KW - histopathology

KW - neurothrombectomy

KW - porcine

KW - preclinical

UR - http://www.scopus.com/inward/record.url?scp=85062455045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062455045&partnerID=8YFLogxK

U2 - 10.1177/0192623319826066

DO - 10.1177/0192623319826066

M3 - Article

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

ER -